1
|
Sesso G, Bargnesi F, Mutti G, Berloffa S, Viglione V, Fantozzi P, Tolomei G, Guccione F, Muratori P, Milone A, Masi G. Extended-Release Lithium Treatment for Adolescents with Bipolar Disorder with or Without Comorbid Autism Spectrum Disorder: Protocol of a Longitudinal Prospective Naturalistic Study for the Assessment of Efficacy and Tolerability. J Clin Med 2024; 13:6196. [PMID: 39458145 PMCID: PMC11508904 DOI: 10.3390/jcm13206196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2024] [Revised: 10/09/2024] [Accepted: 10/11/2024] [Indexed: 10/28/2024] Open
Abstract
Background: Lithium is the gold-standard treatment for Bipolar Disorder (BD) in both adults and adolescents, effectively managing mood episodes and reducing suicide risk. While its efficacy in neurotypical youth is well established, its use in adolescents with Autism Spectrum Disorder (ASD) and comorbid BD remains under-researched. Here, we present the protocol for a study aiming to evaluate the efficacy and tolerability of Extended-Release Lithium Salts in treating adolescents with BD and comorbid ASD compared to neurotypical BD patients. Methods: This longitudinal prospective naturalistic comparative study will enroll lithium-naïve adolescents aged 12-18 with BD, with or without comorbid ASD, from the Department of Child and Adolescent Psychiatry and Psychopharmacology. Participants will be followed for six months while receiving Extended-Release Lithium Salts treatment. Primary outcomes will include mood instability, suicidality, emotional dysregulation, and aggression, assessed through a range of clinical rating scales and diagnostic tools at baseline, three months, and six months. Secondary outcomes will focus on the safety and tolerability of Extended-Release Lithium Salts, with measures including side effect ratings, physical exams, and laboratory tests. Results: We hypothesize that Extended-Release Lithium Salts will demonstrate non-inferiority in treating BD symptoms in adolescents with comorbid ASD compared to those without ASD. Conclusions: This study is poised to fill a significant gap in the literature by providing critical data on the use of lithium for adolescents with BD and ASD. Findings will inform clinical practice and future research, potentially guiding more personalized treatment approaches for this complex and vulnerable population.
Collapse
Affiliation(s)
- Gianluca Sesso
- IMT School for Advanced Studies, 55100 Lucca, Italy;
- Developmental Psychiatry and Psychopharmacology Unit, IRCCS Stella Maris Foundation, 56128 Pisa, Italy; (S.B.); (V.V.); (P.F.); (G.T.); (F.G.); (A.M.); (G.M.)
| | - Francesca Bargnesi
- Department of Clinical and Experimental Medicine, University of Pisa, 56122 Pisa, Italy; (F.B.); (G.M.)
| | - Giulia Mutti
- Department of Clinical and Experimental Medicine, University of Pisa, 56122 Pisa, Italy; (F.B.); (G.M.)
| | - Stefano Berloffa
- Developmental Psychiatry and Psychopharmacology Unit, IRCCS Stella Maris Foundation, 56128 Pisa, Italy; (S.B.); (V.V.); (P.F.); (G.T.); (F.G.); (A.M.); (G.M.)
| | - Valentina Viglione
- Developmental Psychiatry and Psychopharmacology Unit, IRCCS Stella Maris Foundation, 56128 Pisa, Italy; (S.B.); (V.V.); (P.F.); (G.T.); (F.G.); (A.M.); (G.M.)
| | - Pamela Fantozzi
- Developmental Psychiatry and Psychopharmacology Unit, IRCCS Stella Maris Foundation, 56128 Pisa, Italy; (S.B.); (V.V.); (P.F.); (G.T.); (F.G.); (A.M.); (G.M.)
| | - Greta Tolomei
- Developmental Psychiatry and Psychopharmacology Unit, IRCCS Stella Maris Foundation, 56128 Pisa, Italy; (S.B.); (V.V.); (P.F.); (G.T.); (F.G.); (A.M.); (G.M.)
| | - Fulvio Guccione
- Developmental Psychiatry and Psychopharmacology Unit, IRCCS Stella Maris Foundation, 56128 Pisa, Italy; (S.B.); (V.V.); (P.F.); (G.T.); (F.G.); (A.M.); (G.M.)
| | - Pietro Muratori
- Developmental Psychiatry and Psychopharmacology Unit, IRCCS Stella Maris Foundation, 56128 Pisa, Italy; (S.B.); (V.V.); (P.F.); (G.T.); (F.G.); (A.M.); (G.M.)
| | - Annarita Milone
- Developmental Psychiatry and Psychopharmacology Unit, IRCCS Stella Maris Foundation, 56128 Pisa, Italy; (S.B.); (V.V.); (P.F.); (G.T.); (F.G.); (A.M.); (G.M.)
| | - Gabriele Masi
- Developmental Psychiatry and Psychopharmacology Unit, IRCCS Stella Maris Foundation, 56128 Pisa, Italy; (S.B.); (V.V.); (P.F.); (G.T.); (F.G.); (A.M.); (G.M.)
| |
Collapse
|
2
|
Karamantziani T, Pouliakis A, Xanthos T, Ekmektzoglou K, Paliatsiou S, Sokou R, Iacovidou N. The Effect of Oral Iron Supplementation/Fortification on the Gut Microbiota in Infancy: A Systematic Review and Meta-Analysis. CHILDREN (BASEL, SWITZERLAND) 2024; 11:231. [PMID: 38397343 PMCID: PMC10887499 DOI: 10.3390/children11020231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Revised: 02/05/2024] [Accepted: 02/08/2024] [Indexed: 02/25/2024]
Abstract
(1) Background: Iron is an essential metal for the proper growth and neurodevelopment of infants. To prevent and treat iron deficiency, iron supplementation or fortification is often required. It has been shown, though, that it affects the synthesis of gut microbiota. (2) Methods: This paper is a systematic review and meta-analysis of the effect of oral iron supplementation/fortification on the gut microbiota in infancy. Studies in healthy neonates and infants who received per os iron with existing data on gut microbiota were included. Three databases were searched: PUBMED, Scopus, and Google Scholar. Randomized controlled trials (RCTs) were included. Quality appraisal was assessed using the ROB2Tool. (3) Results: A total of six RCTs met inclusion criteria for a systematic review, and four of them were included in the meta-analysis using both the fixed and random effects methods. Our results showed that there is very good heterogeneity in the iron group (I2 = 62%), and excellent heterogeneity in the non-iron group (I2 = 98%). According to the meta-analysis outcomes, there is a 10.3% (95% CI: -15.0--5.55%) reduction in the bifidobacteria population in the iron group and a -2.96% reduction for the non-iron group. There is a confirmed difference (p = 0.02) in the aggregated outcomes between iron and non-iron supplement, indicative that the bifidobacteria population is reduced when iron supplementation is given (total reduction 6.37%, 95%CI: 10.16-25.8%). (4) Conclusions: The abundance of bifidobacteria decreases when iron supplementation or fortification is given to infants.
Collapse
Affiliation(s)
- Theoni Karamantziani
- B’ Neonatal Intensive Care Unit and Neonatal High Dependency Unit, “Aghia Sofia” General Children’s Hospital, 11527 Athens, Greece;
| | - Abraham Pouliakis
- 2nd Department of Pathology, “Attikon” University Hospital, National and Kapodistrian University of Athens, 12464 Athens, Greece
| | - Theodoros Xanthos
- School of Health Sciences, University of West Attica, 12243 Athens, Greece;
| | | | - Styliani Paliatsiou
- 2nd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Aretaieio Hospital, 11528 Athens, Greece;
| | - Rozeta Sokou
- Neonatal Intensive Care Unit, “Agios Panteleimon” General Hospital of Nikea, 3 D. Mantouvalou Str., Nikea, 18454 Piraeus, Greece;
| | - Nicoletta Iacovidou
- Neonatal Department, Aretaieio Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece;
| |
Collapse
|
3
|
Sierakowska A, Roszak M, Lipińska M, Bieniasiewicz A, Łabuz-Roszak B. AUTISM SPECTRUM DISORDER AND SCHIZOPHRENIA - SIMILARITIES BETWEEN THE TWO DISORDERS WITH A CASE REPORT OF A PATIENT WITH DUAL DIAGNOSIS. POLSKI MERKURIUSZ LEKARSKI : ORGAN POLSKIEGO TOWARZYSTWA LEKARSKIEGO 2023; 51:172-177. [PMID: 37254766 DOI: 10.36740/merkur202302111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
This paper presents the genetic, molecular and neuroanatomical similarities between autism spectrum disorder (ASD) and schizophrenia using the case report of a 34-year-old female patient with a previous diagnosis of schizophrenia as an example. As a result of repeat hospitalization, expanded history, psychological testing and verification of persistent symptoms of psychopathology, a cooccurring diagnosis of autism spectrum disorder was made.
Collapse
Affiliation(s)
- Alicja Sierakowska
- STUDENT ASSOCIATION OF NEUROLOGY AT THE DEPARTMENT OF NEUROLOGY, INSTITUTE OF MEDICAL SCIENCES, OPOLE UNIVERSITY, OPOLE, POLAND
| | - Mateusz Roszak
- STUDENT ASSOCIATION OF NEUROLOGY AT THE DEPARTMENT OF NEUROLOGY, INSTITUTE OF MEDICAL SCIENCES, OPOLE UNIVERSITY, OPOLE, POLAND
| | - Milena Lipińska
- DEPARTMENT OF PSYCHIATRY, ST. JADWIGA REGIONAL SPECIALIZED HOSPITAL, OPOLE, POLAND
| | - Anna Bieniasiewicz
- DEPARTMENT OF NEUROLOGY, INSTITUTE OF MEDICAL SCIENCES, UNIVERSITY OF OPOLE, OPOLE, POLAND; DEPARTMENT OF NEUROLOGY, ST. JADWIGA REGIONAL SPECIALIZED HOSPITAL, OPOLE, POLAND
| | - Beata Łabuz-Roszak
- DEPARTMENT OF NEUROLOGY, INSTITUTE OF MEDICAL SCIENCES, UNIVERSITY OF OPOLE, OPOLE, POLAND; DEPARTMENT OF NEUROLOGY, ST. JADWIGA REGIONAL SPECIALIZED HOSPITAL, OPOLE, POLAND
| |
Collapse
|